<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396587</url>
  </required_header>
  <id_info>
    <org_study_id>NAESHO</org_study_id>
    <nct_id>NCT04396587</nct_id>
  </id_info>
  <brief_title>Non-analgesic Effects Produced by Equipotent Analgesic Doses of Sufentanil, Hydromorphone, and Oxycodone</brief_title>
  <official_title>Non-analgesic Effects Produced by Equipotent Analgesic Doses of Sufentanil, Hydromorphone, and Oxycodone in Female Patients Before Anesthesia Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to investigate Non-analgesic Effects Produced by Equipotent Analgesic Doses
      of Sufentanil, Hydromorphone, and Oxycodone in female patients. Methods: A total of 60
      patients were randomly divided into 3 groups, with 20 patients in each group.
      Sufentanil(0.1μg/kg), Hydromorphone(20μg/kg), or Oxycodone(60μg/kg) was administered before
      anesthesia induction. Bispectral Index (BIS), Respiratory rate(RR), other non-analgesic
      effects at Tb (entering room), T0 (drug administration), T1 (2min), T2 (4min), T3(6min),
      T4(8min), T5(10min), T6(20min) were recorded.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>20 minutes after administration</time_frame>
    <description>Number of breaths per minut</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bispectral Index</measure>
    <time_frame>20 minutes after administration</time_frame>
    <description>bispectral index(BIS): assessing the sedation, placed on the patient's forehead, BIS values 0-100, and the higher score means patients are more conscious</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dizziness</measure>
    <time_frame>20 minutes after administration</time_frame>
    <description>a temporary feeling that your sense of balance is not good and that you may fall down</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>itch</measure>
    <time_frame>20 minutes after administration</time_frame>
    <description>itch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nausea or vomiting</measure>
    <time_frame>20 minutes after administration</time_frame>
    <description>nausea or vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drowsiness</measure>
    <time_frame>20 minutes after administration</time_frame>
    <description>drowsiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sweating</measure>
    <time_frame>20 minutes after administration</time_frame>
    <description>sweating</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Opioid Use</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Sufentanil(0.1μg/kg), Hydromorphone(20μg/kg), or Oxycodone(60μg/kg) was administered before anesthesia induction.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Sufentanil(0.1μg/kg), Hydromorphone(20μg/kg), or Oxycodone(60μg/kg) was administered before anesthesia induction.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Sufentanil(0.1μg/kg), Hydromorphone(20μg/kg), or Oxycodone(60μg/kg) was administered before anesthesia induction.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists GradeⅠ－II;

          -  Patients undergo low-risk elective surgery for benign diseases (including laparoscopic
             ovarian cyst removal, laparoscopic tubal ligation, laparoscopic tubal drainage, breast
             operation, thyroid operation, etc) ;

          -  Aged 18-45 years;

          -  Body Mass Index 18-25kg/m2, weight 40-65 kilograms;

          -  Agreed to participate in the research

        Exclusion Criteria:

          -  Difficult airway;

          -  upper respiratory tract infection within 2 weeks;

          -  history of allergy or long-term use of propofol and opioids;

          -  self-rating anxiety scale before operation indicates anxiety;

          -  pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qi Yan, MD</last_name>
    <phone>13811319638</phone>
    <email>yanqi04@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Feng, MD</last_name>
    <phone>01088325581</phone>
    <email>yifeng65@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 16, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Yanqi</investigator_full_name>
    <investigator_title>attending</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

